CB-011

Asset

Gene-edited allogeneic CAR T cells target BCMA-expressing myeloma cells.

Stage: Phase 1
Modality: Cell therapy
Target: TNFRSF17; 1
Indication: 1,942
Trials: 1
Developer

Indications

1

Relapsed refractory multiple myeloma
Phase 1, Recruiting, NCT05722418, clinicaltrials.gov, 16 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials1,942
Evidence for its targets2
Competitors4
Signals3

Every asset’s record: target, stage, trials and the evidence behind it.